INTUNIV(TM) - Shire Files Suit Against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd.

By Shire Plc, PRNE
Thursday, April 22, 2010

DUBLIN and PHILADELPHIA, April 23, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that its subsidiary Shire LLC has filed
a lawsuit in the U.S. District Court for the District of Delaware against
Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd
(collectively "Teva") for the infringement of U.S. Patent Nos. 6,287,599 (the
'599 patent) and 6,811,794 (the '794 patent).

The lawsuit results from an Abbreviated New Drug Application (ANDA) filed
by Teva for generic versions of 1 mg, 2 mg, 3 mg and 4 mg guanfacine
hydrochloride extended release tablets, INTUNIV(TM), which seeks to market
such generic products before the expiration of the '599 and '794 patents.
Teva's ANDA did not challenge, and the lawsuit does not currently assert, the
third Orange Book listed patent (U.S. Patent No. 5,854,290, Use of Guanfacine
in the Treatment of Behavioral Disorders) which expires in 2015. The
regulatory exclusivity period for INTUNIV(TM) runs through September 2, 2012.

Notes to editors


Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire's in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:

ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the
event such risks or uncertainties materialize, the Company's results could be
materially adversely affected. The risks and uncertainties include, but are
not limited to, risks associated with: the inherent uncertainty of research,
development, approval, reimbursement, manufacturing and commercialization of
the Company's Specialty Pharmaceutical and Human Genetic Therapies products,
as well as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the Company's
products; the Company's ability to manufacture its products in sufficient
quantities to meet demand; the impact of competitive therapies on the
Company's products; the Company's ability to register, maintain and enforce
patents and other intellectual property rights relating to its products; the
Company's ability to obtain and maintain government and other third-party
reimbursement for its products; and other risks and uncertainties detailed
from time to time in the Company's filings with the Securities and Exchange

For further information please contact: Investor Relations: Clea Rosenfeld (Rest of the World), +44-1256-894-160; Eric Rojas (North America), +1-781-482-0999; Media: Jessica Mann (Rest of the World), +44-1256 894-280; Matthew Cabrey (North America, Specialty Pharma, +1-484-595-8248

will not be displayed